Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy
Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited. With the exception of the commercialized CD19 CAR-T for hematolog...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2020/2454907 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555012412145664 |
|---|---|
| author | Lichen Zhu Xiaomei Yang Dani Zhong Shenxia Xie Wei Shi Yangzi Li Xiaoqiong Hou HuaYao Huihui Zhou Minlong Zhao Ziqiang Ding Xinyue Zhao Fengzhen Mo Shihua Yin Aiqun Liu Xiaoling Lu |
| author_facet | Lichen Zhu Xiaomei Yang Dani Zhong Shenxia Xie Wei Shi Yangzi Li Xiaoqiong Hou HuaYao Huihui Zhou Minlong Zhao Ziqiang Ding Xinyue Zhao Fengzhen Mo Shihua Yin Aiqun Liu Xiaoling Lu |
| author_sort | Lichen Zhu |
| collection | DOAJ |
| description | Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited. With the exception of the commercialized CD19 CAR-T for hematological malignancies and other CAR-T therapies aiming mostly at extracellular antigens achieving great success, the rareness and scarcity of TCR-like CAR-T therapies might be due to their current status and limitations. This review provides the probable optimized initiatives for improving TCR-like CAR-T reprogramming and discusses single-domain antibodies administered as an alternative to conventional scFvs and secreted by CAR-T cells, which might be of great value to the development of CAR-T immunotherapies for intracellular antigens. |
| format | Article |
| id | doaj-art-c63e1f7f861a46d5bcea752b80cbcf57 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-c63e1f7f861a46d5bcea752b80cbcf572025-02-03T05:49:54ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/24549072454907Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer TherapyLichen Zhu0Xiaomei Yang1Dani Zhong2Shenxia Xie3Wei Shi4Yangzi Li5Xiaoqiong Hou6HuaYao7Huihui Zhou8Minlong Zhao9Ziqiang Ding10Xinyue Zhao11Fengzhen Mo12Shihua Yin13Aiqun Liu14Xiaoling Lu15Nanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaNanobody Research Center, Guangxi Medical University, Nanning, Guangxi 530021, ChinaRetargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited. With the exception of the commercialized CD19 CAR-T for hematological malignancies and other CAR-T therapies aiming mostly at extracellular antigens achieving great success, the rareness and scarcity of TCR-like CAR-T therapies might be due to their current status and limitations. This review provides the probable optimized initiatives for improving TCR-like CAR-T reprogramming and discusses single-domain antibodies administered as an alternative to conventional scFvs and secreted by CAR-T cells, which might be of great value to the development of CAR-T immunotherapies for intracellular antigens.http://dx.doi.org/10.1155/2020/2454907 |
| spellingShingle | Lichen Zhu Xiaomei Yang Dani Zhong Shenxia Xie Wei Shi Yangzi Li Xiaoqiong Hou HuaYao Huihui Zhou Minlong Zhao Ziqiang Ding Xinyue Zhao Fengzhen Mo Shihua Yin Aiqun Liu Xiaoling Lu Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy Journal of Immunology Research |
| title | Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy |
| title_full | Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy |
| title_fullStr | Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy |
| title_full_unstemmed | Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy |
| title_short | Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy |
| title_sort | single domain antibody based tcr like car t a potential cancer therapy |
| url | http://dx.doi.org/10.1155/2020/2454907 |
| work_keys_str_mv | AT lichenzhu singledomainantibodybasedtcrlikecartapotentialcancertherapy AT xiaomeiyang singledomainantibodybasedtcrlikecartapotentialcancertherapy AT danizhong singledomainantibodybasedtcrlikecartapotentialcancertherapy AT shenxiaxie singledomainantibodybasedtcrlikecartapotentialcancertherapy AT weishi singledomainantibodybasedtcrlikecartapotentialcancertherapy AT yangzili singledomainantibodybasedtcrlikecartapotentialcancertherapy AT xiaoqionghou singledomainantibodybasedtcrlikecartapotentialcancertherapy AT huayao singledomainantibodybasedtcrlikecartapotentialcancertherapy AT huihuizhou singledomainantibodybasedtcrlikecartapotentialcancertherapy AT minlongzhao singledomainantibodybasedtcrlikecartapotentialcancertherapy AT ziqiangding singledomainantibodybasedtcrlikecartapotentialcancertherapy AT xinyuezhao singledomainantibodybasedtcrlikecartapotentialcancertherapy AT fengzhenmo singledomainantibodybasedtcrlikecartapotentialcancertherapy AT shihuayin singledomainantibodybasedtcrlikecartapotentialcancertherapy AT aiqunliu singledomainantibodybasedtcrlikecartapotentialcancertherapy AT xiaolinglu singledomainantibodybasedtcrlikecartapotentialcancertherapy |